Brain Cancer

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

An NDA seeking the approval of TLX101-Px for characterizing treatment-related changes in recurrent or progressive glioma has been accepted by the FDA.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses innovations in brain surgery and the importance of balancing oncological and functional outcomes.

Researchers at Northwestern Medicine have developed a new and faster approach to determine if a treatment for the brain cancer glioblastoma is working.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.